Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.

For subscribers

Novo Nordisk CEO rakes in cash in record year

For subscribers

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Foto: Stine Bidstrup

Potential blockbuster submitted by Novo Nordisk for European approval

For subscribers

Christophe Bourdon, CEO at Leo Pharma | Foto: Leo Pharma / Pr

Leo Pharma to reuse model from failed acquisition

For subscribers

China accepts regulatory filing for ALK allergy tablet

For subscribers

Dupixent becomes ninefold blockbuster

For subscribers

ALK forecasts lower growth in 2023 than strong 2022 result
The allergy firm thinks 7–11% growth in 2023 is likely after a strong 2022 performance meets an upgraded guidance from the summer.
For subscribers
Europe pharma sector risks lagging the world, say drug chiefs
Chief executives of Novartis, GSK, and Novo Nordisk say healthcare must become an urgent priority in Europe, else the region risks falling behind the rest of the world.
For subscribers
Eli Lilly raises 2023 expectations
A new forecasted tax rate for the fiscal year to come means Lilly can upgrade some expectations, reveals the company’s fourth-quarter report.
For subscribers
Novo Nordisk CEO says obesity is "obviously a big market"
Analysts value the future obesity market in the billions of dollars – and though coy about his own expectations, CEO Lars Fruergaard Jørgensen says Novo Nordisk has ”a very, very significant opportunity.”
For subscribers
Supply issues to continue in 2023, reports Novo Nordisk
Investing massively into increasing production capacity, Novo Nordisk hopes to increase its drug supply, though 2023 will still see ”periodic supply constraints,” informs Novo CFO Karsten Munk Knudsen.
For subscribers
Novo Nordisk sues Viatris over copycat Wegovy
A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.
For subscribers
Novartis beats Kesimpta sales expectations in Q4
Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.
For subscribers
Analyst: Strong Novo Nordisk outlook should satisfy investors
An analyst has looked over the Danish drugmaker’s annual report, concluding that there are enough elements – including expected 2023 sales growth of up to 19% – for a Novo stock boost.
For subscribers
Studies of Wegovy in higher-than-approved doses begin
In January, Novo Nordisk initiated two late-stage studies of semaglutide, the substance in both obesity drug Wegovy and diabetes drug Ozempic, in higher doses than currently approved.
For subscribers
Rare Disease business comes in slightly below expectations for Novo Nordisk
Though hemophilia drug Novoseven surprised positively in Q4, Novo’s Rare Disease segment was let down by its treatments for rare endocrine disorders.
For subscribers
Novo Nordisk meets upgraded guidance, sets new revenue record
The Danish drugmaker’s top and bottom lines have increased considerably.
For subscribers
Novo Nordisk doubles obesity sales in 2022
Wegovy and Saxenda set new records in fiscal 2022, during which particularly the former gave a strong performance near the end, exceeding analysts Q4 expectations by millions of dollars.
For subscribers
Novo Nordisk predicts wide range for 2023 sales growth
The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)
For subscribers
Pfizer hopes Covid-19 sales will increase in the long run
Citing existing stockpiles around the world, Pfizer does not think it can increase sales of its two Covid-19 products in 2023 – but this development will reverse in the future.
For subscribers
Amgen takes on Abbvie blockbuster Humira with unusual price plan
Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.
For subscribers
Nordea cuts Lundbeck share target week before annual report
The bank spots a risk of Lundbeck’s 2023 guidance disappointing analysts who have set expectations too high.
For subscribers
Analysts await Novo Nordisk's 2023 guidance with high expectations
The Danish drugmaker publishes its annual report for a concluded fiscal year tomorrow, Wednesday – and as customary, onlookers want to know what’s next for Novo Nordisk.
For subscribers
Orphazyme trio founds new firm focused on neurology and rare diseases
Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.
For subscribers
Novo Nordisk wins case in US appeals court
Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.
For subscribers
Alzheimer's drug wins priority review in Japan
Biogen and Eisai ’s Alzheimer’s treatment candidate gains access to faster case processing by authorities in Japan.
For subscribers

Latest news

See all

Jobs

See all jobs

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Novo Nordisk hopes to retain employees with share gift

Novo Nordisk CEO rakes in cash in record year

Potential blockbuster submitted by Novo Nordisk for European approval

Leo Pharma to reuse model from failed acquisition

China accepts regulatory filing for ALK allergy tablet

Dupixent becomes ninefold blockbuster

ALK forecasts lower growth in 2023 than strong 2022 result

Europe pharma sector risks lagging the world, say drug chiefs

Eli Lilly raises 2023 expectations

Novo Nordisk CEO says obesity is "obviously a big market"

Supply issues to continue in 2023, reports Novo Nordisk

Novo Nordisk sues Viatris over copycat Wegovy

Novartis beats Kesimpta sales expectations in Q4

Analyst: Strong Novo Nordisk outlook should satisfy investors

Studies of Wegovy in higher-than-approved doses begin

Rare Disease business comes in slightly below expectations for Novo Nordisk

Novo Nordisk meets upgraded guidance, sets new revenue record

Novo Nordisk doubles obesity sales in 2022

Novo Nordisk predicts wide range for 2023 sales growth

Pfizer hopes Covid-19 sales will increase in the long run

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Nordea cuts Lundbeck share target week before annual report

Analysts await Novo Nordisk's 2023 guidance with high expectations

Orphazyme trio founds new firm focused on neurology and rare diseases

Novo Nordisk wins case in US appeals court

Alzheimer's drug wins priority review in Japan

Latest news

Jobs